Segui
William D. Figg, PhD
William D. Figg, PhD
University of Buckingham, Medical School | University of Oxford, Department of Chemistry
Email verificata su buckingham.ac.uk - Home page
Titolo
Citata da
Citata da
Anno
Lack of activity of recombinant HIF prolyl hydroxylases (PHDs) on reported non-HIF substrates
ME Cockman, K Lippl, YM Tian, HB Pegg, WD Figg, MI Abboud, R Heilig, ...
Elife 8, e46490, 2019
922019
Structural basis of prolyl hydroxylase domain inhibition by molidustat
WD Figg Jr, MA McDonough, R Chowdhury, Y Nakashima, Z Zhang, ...
ChemMedChem 16 (13), 2082-2088, 2021
312021
Aromatase inhibitor plus ovarian suppression as adjuvant therapy in premenopausal women with breast cancer
WD Figg, K Cook, R Clarke
Cancer biology & therapy 15 (12), 1586-1587, 2014
272014
Structure‐activity relationship and crystallographic studies on 4‐hydroxypyrimidine HIF prolyl hydroxylase domain inhibitors
JP Holt‐Martyn, R Chowdhury, A Tumber, TL Yeh, MI Abboud, K Lippl, ...
ChemMedChem 15 (3), 270-273, 2020
262020
Monitor tumor burden with circulating tumor DNA
WD Figg II, J Reid
Cancer biology & therapy 14 (8), 697-698, 2013
242013
Multi-institutional Study of Outcomes After Pediatric Heart Transplantation: Candidate Gene Polymorphism Analysis of ABCC2
GJ Burckart, WD Figg, MM Brooks, DJ Green, SM Troutman, R Ferrell, ...
The Journal of Pediatric Pharmacology and Therapeutics 19 (1), 16-24, 2014
232014
Cabazitaxel: filling one of the gaps in the treatment of prostate cancer
WD Figg, WD Figg, II
Cancer Biology & Therapy 10 (12), 1233-1234, 2010
182010
Detectible mosaic truncating PPM1D mutations, age and breast cancer risk
MJ Machiela, TA Myers, CJ Lyons, R Koster, WD Figg Jr, LM Colli, ...
Journal of human genetics 64 (6), 545-550, 2019
102019
Studies on spiro [4.5] decanone prolyl hydroxylase domain inhibitors
JP Holt-Martyn, A Tumber, MZ Rahman, K Lippl, W Figg, MA McDonough, ...
MedChemComm 10 (4), 500-504, 2019
102019
How do you want your steak prepared? The impact of meat consumption and preparation on prostate cancer
WD Figg
Cancer Biology & Therapy 13 (12), 1141-1142, 2012
82012
Structure-guided optimisation of N-hydroxythiazole-derived inhibitors of factor inhibiting hypoxia-inducible factor-α
TP Corner, RZR Teo, Y Wu, E Salah, Y Nakashima, G Fiorini, A Tumber, ...
Chemical Science 14 (43), 12098-12120, 2023
72023
Structural basis for binding of the renal carcinoma target hypoxia‐inducible factor 2α to prolyl hydroxylase domain 2
WD Figg Jr, G Fiorini, R Chowdhury, Y Nakashima, A Tumber, ...
Proteins: Structure, Function, and Bioinformatics 91 (11), 1510-1524, 2023
62023
Association Between Thiopurine S-Methyltransferase (TPMT) Genetic Variants and Infection in Pediatric Heart Transplant Recipients Treated With Azathioprine: A …
DJ Green, SQ Duong, GJ Burckart, T Sissung, DK Price, WD Figg Jr, ...
The Journal of Pediatric Pharmacology and Therapeutics 23 (2), 106-110, 2018
42018
Enzalutamide for treatment of CRPC: Rationale for sequencing and potential clinical biomarker for resistance
SE Lochrin, WD Figg, SP Finn
Cancer Biology & Therapy 16 (2), 201-203, 2015
12015
Human prolyl hydroxylase domain 2 reacts with O2 and 2-oxoglutarate to enable formation of inactive Fe(III).2OG.hypoxia-inducible-factor α complexes
G Fiorini, SA Marshall, WD Figg Jr, WK Myers, L Brewitz, CJ Schofield
Scientific Reports 14 (1), 26162, 2024
2024
Structural and mechanistic studies on PHD2 and the discovery of potential inhibitors
WD Figg Jr
University of Oxford, 2022
2022
HIF-prolyl-hydroxylase 2 clinical inhibitor complex structure and XChem fragment-based screen obtained with succinate co-product used as a crystallisation tool
WD Figg Jr, MA McDonough, Y Nakashima, R Chowdhury, CJ Schofield
Acta Crystallographica Section A: Foundations and Advances 77, C1193-C1193, 2021
2021
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–17